Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Searching for new cardiovascular drugs: towards improved systems for drug screening?

Silvester, Nicole C. and George, Christopher H. 2011. Searching for new cardiovascular drugs: towards improved systems for drug screening? Expert Opinion on Drug Discovery 6 (11) , pp. 1155-1170. 10.1517/17460441.2011.625652

This is the latest version of this item.

PDF - Accepted Post-Print Version
Download (249kB) | Preview


Introduction: The pharmaceutical industry urgently needs new ways of profiling the safety and efficacy of new cardiovascular (CV) drugs and more effectively transitioning these compounds through the stages of CV drug screening. This article reviews new technologies and methodological innovations and assesses whether these frameworks offer improved solutions to the problems facing the contemporary CV drug development. Areas covered: The article comprises literature derived from a systematic search (from 2000 onwards) using the US patent office and ESP@CENET search engines as well as through multiple Boolean terms. The article focuses on patents relating to technologies and resources and categorises the patents according to their niche in the CV drug screening landscape. Expert opinion: The CV drug pipeline is stalling due to the inability of many contemporary drug screening frameworks to discriminate between safe, efficacious therapy and hazardous off-target effect. Given the current limitations of drug screening frameworks, there is little scope for expanding the CV drug portfolio with newer, safer drugs with improved mechanisms of action. New screening modalities are urgently needed. Searches reveal that there are few examples of truly new technologies and systems in the patent literature. This apparent failure to revamp facets of the CV drug screening process can only perpetuate the inability of current platforms to improve the CV drug pipeline. Consequently, with few exceptions, there is stagnation in pre-clinical assay design that limits the pharmaceutical industry's ability to search for new drugs in new and more effective ways.

Item Type: Article
Date Type: Published Online
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
Publisher: Taylor & Francis
ISSN: 1746-0441
Funders: British Heart Foundation / Heart Research UK
Date of First Compliant Deposit: 17 June 2016
Last Modified: 10 Mar 2020 20:19

Available Versions of this Item

  • Searching for new cardiovascular drugs: towards improved systems for drug screening? (deposited 17 Jun 2016 15:26) [Currently Displayed]

Citation Data

Cited 6 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics